Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Feb;35(8):501-7.
doi: 10.1093/eurheartj/eht457. Epub 2013 Oct 17.

Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)

Lluís Mont  1 , Felipe Bisbal, Antonio Hernández-Madrid, Nicasio Pérez-Castellano, Xavier Viñolas, Angel Arenal, Fernando Arribas, Ignacio Fernández-Lozano, Andrés Bodegas, Albert Cobos, Roberto Matía, Julián Pérez-Villacastín, José M Guerra, Pablo Ávila, María López-Gil, Victor Castro, José Ignacio Arana, Josep Brugada; SARA investigators
Collaborators, Affiliations
Randomized Controlled Trial

Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study)

Lluís Mont et al. Eur Heart J. 2014 Feb.

Abstract

Background: Catheter ablation (CA) is a highly effective therapy for the treatment of paroxysmal atrial fibrillation (AF) when compared with antiarrhythmic drug therapy (ADT). No randomized studies have compared the two strategies in persistent AF. The present randomized trial aimed to compare the effectiveness of CA vs. ADT in treating persistent AF.

Methods and results: Patients with persistent AF were randomly assigned to CA or ADT (excluding patients with long-standing persistent AF). Primary endpoint at 12-month follow-up was defined as any episode of AF or atrial flutter lasting >24 h that occurred after a 3-month blanking period. Secondary endpoints were any atrial tachyarrhythmia lasting >30 s, hospitalization, and electrical cardioversion. In total, 146 patients were included (aged 55 ± 9 years, 77% male). The ADT group received class Ic (43.8%) or class III drugs (56.3%). In an intention-to-treat analysis, 69 of 98 patients (70.4%) in the CA group and 21 of 48 patients (43.7%) in the ADT group were free of the primary endpoint (P = 0.002), implying an absolute risk difference of 26.6% (95% CI 10.0-43.3) in favour of CA. The proportion of patients free of any recurrence (>30 s) was higher in the CA group than in the ADT group (60.2 vs. 29.2%; P < 0.001) and cardioversion was less frequent (34.7 vs. 50%, respectively; P = 0.018).

Conclusion: Catheter ablation is superior to medical therapy for the maintenance of sinus rhythm in patients with persistent AF at 12-month follow-up.

Clinical trial registration information: NCT00863213 (http://clinicaltrials.gov/ct2/show/NCT00863213).

Keywords: Antiarrhythmic drug; Atrial fibrillation; Atrial flutter; Catheter ablation; Clinical trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study design flowchart (CONSORT flow diagram). CA, catheter ablation; ADT, antiarrhythmic drug therapy.
Figure 2
Figure 2
Survival curves for the primary endpoint.
See this image and copyright information in PMC

Comment in

References

    1. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clementy J, Haissaguerre M. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118:2498–2505. doi:10.1161/CIRCULATIONAHA.108.772582. - DOI - PubMed
    1. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, Paglino G, Mazzone P, Sora N, Greiss I, Santagostino A, LiVolsi L, Pappone N, Radinovic A, Manguso F, Santinelli V. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. J Am Coll Cardiol. 2006;48:2340–2347. doi:10.1016/j.jacc.2006.08.037. - DOI - PubMed
    1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–2747. doi:10.1093/eurheartj/ehs253. - DOI - PubMed
    1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:e101. doi:10.1016/j.jacc.2010.09.013. - DOI - PubMed
    1. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004549. doi:10.1161/JAHA.112.004549. - DOI - PMC - PubMed

Publication types

Substances

Associated data